Pricing Log in Create free account

Capricor Therapeutics, Inc. (CAPR) vs REGENXBIO Inc. (RGNX)

Capricor Therapeutics, Inc. and REGENXBIO Inc. are both Biotechnology companies. Capricor Therapeutics, Inc. and REGENXBIO Inc. are of similar size ($500.0M and $487.2M). REGENXBIO Inc. grew revenue faster over the last twelve months: −4.59% against −11.6%. Capricor Therapeutics, Inc. has the higher net margin (0.00% vs −113.9%) and the lower return on invested capital (−1,019.7% vs 0.00%). Across the 17 metrics below, Capricor Therapeutics, Inc. leads on 10 and REGENXBIO Inc. on 7.

Valuation

Metric CAPR RGNX Biotechnology median
P/E n/m n/m 10.60
P/S 23.51 3.21 9.40
P/B 2.13 3.33 2.13
Price to free cash flow 4.00 n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 13.47 1.61 9.02
Earnings yield (27.10%) (42.52%) (32.88%)
Free cash flow yield 25.00% (31.38%) (23.13%)

Profitability

Metric CAPR RGNX Biotechnology median
Gross margin 100.00% 87.54% 68.51%
Operating margin 0.00% (95.68%) 0.00%
Net margin 0.00% (113.85%) 0.00%
Free cash flow margin 0.00% (100.58%) 0.00%
Return on equity (73.70%) (113.24%) (51.96%)
Return on assets (51.53%) (35.36%) (46.06%)
Return on invested capital (1,019.73%) 0.00% 0.00%

Growth

Metric CAPR RGNX Biotechnology median
Revenue growth (TTM) (11.55%) (4.59%) 6.76%
EPS growth (last fiscal year) (96.52%) 18.08% 29.88%
Revenue growth, 5-year CAGR 85.83% 1.97% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CAPR RGNX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 7.35 4.74 4.97
Net debt to EBITDA 2.99 1.58 1.01

Dividend

Metric CAPR RGNX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CAPR RGNX Biotechnology median
Market cap 500.00m 487.18m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack